Intelligence · Clinical Pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
- Programs
- 2,640
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 199 programs
- George Institute for 119 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
-
pazopanib (GW786034) 400 mg
GlaxoSmithKline
Neoplasms, Breast
1 trial -
pegcrisantaspase
Jazz Pharmaceuticals Ireland Limited
Acute Lymphoblastic Leukemia
1 trial -
pelareorep, Tecentriq 840 mg concentrate for solution for infusion
ONCOLYTICS BIOTECH INC
Patients with advanced or metastatic gastrointestinal (GI) tumors.
1 trial -
pembrolizumab
Hospital Authority, Hong Kong
Locally Recurrent Cancer
1 trial -
pembrolizumab
The University of Hong Kong
T-Cell Lymphoma
1 trial -
pembrolizumab
The First People's Hospital of Lianyungang
Advanced Non-squamous Non-small-cell Lung Cancer
1 trial -
pemetrexed
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
pepinemab + pembrolizumab
VACCINEX, INC.
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
1 trial -
pharmorubicin or pirarubicin
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
ponatinib - Phase 1
Takeda
Chronic Myeloid Leukemia (CML)
1 trial -
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
The First People's Hospital of Lianyungang
HER2-positive Breast Cancer
1 trial -
radiation therapy
Children's Hospital of Fudan University
Brain Tumor
1 trial -
raltitrexed combined with apatinib
Chinese PLA General Hospital
Colorectal Cancer
1 trial -
recombinant human Angiostatin protein
CASI Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
recombinant human endostatin
Peking University Third Hospital
Melanoma
1 trial -
remicade (anti tumor necrosis factor inhibitor)
Hospital Authority, Hong Kong
Takayasu's Arteritis
1 trial -
rezatapopt
PMV Pharmaceuticals
Advanced Solid Tumor
1 trial -
rituximab
United Therapeutics Europe Ltd
Lymphoma
1 trial -
rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab
Merck Sharp and Dohme
non-small cell lung cancer
1 trial -
rolistobart, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830
Merck Sharp and Dohme
Non-small Cell Lung Cancer (NSCLC)
1 trial -
rolistobart, boserolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830
Merck Sharp and Dohme
Non-small Cell Lung Cancer
1 trial -
self-expandable 125I radioactive seeds-loaded-stent
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocellular Carcinoma
1 trial -
silevertinib (BDTX-1535) monotherapy
Blackmores Limited
Non-Small Cell Lung Cancer
1 trial -
sintilimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
sintilimab
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
sintiliman plus LDRT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.
The George Institute
Merkel Cell Carcinoma
1 trial -
ssCART-19
The First People's Hospital of Lianyungang
Relapsed or Refractory Acute Lymphoblastic Leukemia
1 trial -
ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia, Adult B-Cell
1 trial -
sunitinib added to FOLFIRI
BRIGHT MINDS BIOSCIENCES INC.
Metastatic Colorectal Cancer
1 trial -
surufatinib + fulvestrant + chidamide
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
temozolomide
Children's Hospital of Fudan University
Brain and Central Nervous System Tumors
1 trial -
temozolomide
Universal Integrated
Cancer
1 trial -
the standard "3+7" regimen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Newly Diagnosed Acute Myeloid Leukemia (AML)
1 trial -
therapeutic autologous dendritic cells
LISATA THERAPEUTICS, INC.
Melanoma (Skin)
1 trial -
tisotumab vedotin
Genmab A/S
Solid Tumor
1 trial -
toripalimab
The First People's Hospital of Lianyungang
Malignant Melanoma
1 trial -
trifluridine/tipiracil combined with fufuquitinib
The First People's Hospital of Lianyungang
Metastatic Colorectal Cancer
1 trial -
troxacitabine
Takeda
Leukemia
1 trial -
veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
vidutolimod
Regeneron UK Limited
Merkel Cell Carcinoma
1 trial -
vilastobart (XTX101)
Xilio Therapeutics
Advanced Solid Tumor
1 trial -
vinflunine
Bristol-Myers Squibb
Transitional Cell Carcinoma
1 trial -
vistusertib (AZD2014)
Samsung Bioepis NL B.V.
Small Cell Lung Cancer
1 trial -
vitamin C
CNS Pharmaceuticals
Ovarian Cancer
1 trial -
vitamin C
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Non-Small-Cell Lung
1 trial -
volrustomig, Monalizumab
Pari Pharma GmbH
cancerology
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,640 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs